We represented Biosight in Closing Financing to Advance Clinical Oncology Programs

3 December, 2020

Yuval Horn, Assaf Unger & Ana Eiskov represented Biosight  in the impressive second closing.

For more info:

Horn & Co. represented “Savoreat” in the first Food-tech IPO

November 26th

IBA2020 Conference “VirtuallyTogether” will be held on November 18, 2020

November 15, 2020

Congrats to the entire INX Limited team, who made history today by announcing the effectiveness of Security Token IPO

August 26, 2020

Congrats to the entire INX Limited team, who made history today by announcing the effectiveness of Security Token IPO.
Yuval Horn, Assaf Unger and Roy Ribon advised INX on the filing.

For more info

Another important milestone for Zebra Medical Vision Ltd- innovative partnership for AI implementation with Canon USA

August 12, 2020

Another important milestone for Zebra Medical Vision Ltd– innovative partnership for AI implementation with Canon USA. Congratulations to the team at Zebra-Med. Yuval Horn and Uri Dotan of Horn & Co., Law Offices  represented the company.

For more information

Horn & Co. represented Pontifax’s Venture Lending Fund in a $30M Convertible Debt Financing Agreement with ProQR Therapeutics N.V

July 15, 2020

Horn & Co. represented Pontifax’s Venture Lending Fund in a $30M Convertible Debt Financing Agreement with ProQR Therapeutics N.V., a Dutch company traded on Nasdaq, developing transformative RNA therapies for the treatment of severe genetic rare diseases. The Horn & Co. team was led by Yuval Horn and Ohad Mamann. Congratulations to Momi Karako and the rest of the Pontifax team on this impressive transaction.
For more info

Proud to be ranked, again, by IAM Magazine as one of top 4“highly recommended” Israeli firms in intellectual property transactions

June 14, 2020

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4“highly recommended” Israeli firms in intellectual property transactions: “The “well-regarded” Horn & Co. is a market leader when it comes to transactional intellectual property. It shepherds dozens of licensing deals across the line every year – primarily in the life sciences sector, but also increasingly at the ever-blurring boundary between medicine and technology.”. Partner Yuval Horn was noted as one of top 3 “highly recommended” individuals, stating: “Yuval Horn is an authority in the field of medical data licensing; the “bright and practical problem solver” boasts “a broad multidisciplinary knowledge of the law”. Partners Keren Kanir and Ohad Mamann were also recommended as leading individuals.

For more information

Vascular Biogenics Ltd. raises an additional $8.1 million, completing an aggregate $18.1 million raise. Yuval Horn, Keren Kanir and Shimrit Roznek represented VBL in this transaction.

May 13, 2020

For more information

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences

May 4, 2020

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “Life sciences and hi-tech boutique Horn & Co has a premier reputation for its broad industry expertise, with strong skill sets in M&A, corporate finance, IP, research-related issues and commercial partnerships” The firm was further recognized as a leading firm in the fields of Hi-tech and start-ups and IP transactions.
For more information

Proud of our client, Diagnostic Robotics Ltd. that developed a system for detecting COVID-19

March 30, 2020

Proud of our client, Diagnostic Robotics Ltd., developer of a triage and monitoring system for detecting COVID-19. The system was launched for use yesterday by the Israeli Ministry of Health and the major Israeli HMO. Yuval Horn, Keren Kanir, Alon Shafrir and Maya Weiss-Donin advised the company.
For more information

Yuval Horn noted once again as a Thought Leader Global Elite 2020 in Life Sciences by Who’s Who Legal, the only individual from Israel.

February 20, 2020

For more info

“They were providing services to one of the more innovative projects coming out of Israel in blockchain and trying to secure SEC approval for a project, which is very difficult to get.”

January 20, 2020

Proud to have been recognized as a leading firm in the Chambers & Partners Fintech ranking. Partner Yuval Horn was noted as a leading practitioner, described as “a very experienced and known lawyer for many years” who “has a deep understanding of blockchain.”

For more info

Paz Abercohen, Yuval Horn and Yonatan Levinstein of Horn & Co. represented Raziel Therapeutics in its $22 million series C round, led by Pontifax, with participation from existing investors as well as new investors, Catalyst Fund, Quark venture, Peregrine Investments and Wille AG.

December 18, 2019

For more info

Yuval Horn will moderate a panel about AI and eHealth disruption in the medical and lifestyle markets with Markus von Fuchs at the upcoming IBA 6th Biennial Technology Law Conference in Berlin.

October 10, 2019

Join us to listen to panelists Sylvie Luria of the Sheba Medical Center, Kristina Ehle of MoFo, Alberto Prado of Philips Health, Khaled El Emam, and Nikolaus Schumacher of Nambaya.

For more Info:

IBA 6th Biennial Technology Law Conference

Yuval Horn moderated a panel with Rabel Z. Akhund on the regulation of crypto trading platforms.

September 25, 2019

Full room listening to Anthony Provasoli, Seungmin Jasmine, Jiwook Kim, Yoojun Lee of Coinone and Vinay Abuja discuss regulation enacted and considered worldwide.

Yuval Horn moderated, with Doil Son of Yulchon (Seoul) a panel on Data in M&A at the Annual Meeting of the International Bar Association in Seoul.

September 24, 2019

Speakers included John Kuo of Varian, Andrew Kim of Netgear, Stefan Weidert, Ellisa Habbart and Edward J. Lee.

Paz Abercohen of Horn & Co. represented Biolight Life Sciences Ltd. in its investment in Sanoculis Ltd., a medical device company which develops an innovative surgical procedure for treatment of Glaucoma

September 15, 2019

For more Info:

Bio-Light Website

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 5 “highly recommended” Israeli firms in intellectual property transactions

July 2019

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 5 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s technical breadth means that it can cater to an expansive range of clients, while the depth of each practitioner’s expertise still promises quality”. Partner Yuval Horn was noted as one of top 3 “highly recommended” individuals, quoting a recent client with decades of experience in the local market: “he is one of the best IP transactional lawyers in Israel” Partner Ohad Mamann was also recommended as a leading individual.

For more info:

http://www.iam-media.com/patent1000/rankings/Detail.aspx?g=f35c5ba6-3ee4-4cdb-9f7cc2fafaa422a4#Firms__transactions

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “Horn & Co is known for providing top-quality service, particularly to pharmaceutical companies and investors, in relation to IP, commercial agreements, M&A and regulatory matters.” The firm was further recognized as a leading firm in the fields of Hi-tech and start-ups and IP transactions.

April 2019

For more info:

https://www.legal500.com/c/israel/healthcare-and-life-sciences

Yuval Horn, Ohad Mamann and Anat Polyachenko of Horn & Co. represented the shareholders of Famewave Ltd. in the acquisition of Famewave by Kitov Pharmaceuticals Ltd.  (NASDAQ/TASE: KTOV) in consideration for $10 million and a simultaneous investment of $3.5 million by certain shareholders in Kitov. Famewave Ltd. was set up by the former shareholders of cCAM Biotherapeutics Ltd., which we represented in the acquisition by MSD in 2015.

March 2019

For more info:

https://www.globenewswire.com/news-release/2019/03/14/1753238/0/en/Kitov-to-Acquire-Clinical-Stage-Candidate-CM-24-Creating-a-Transformational-Immuno-Oncology-Company.html

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2018 ranking by fields of expertise.

March 2019

Firm was ranked a leader (“tier 1”) firm in the fields of Hi-Tech and Intellectual Property Transactions, and as an outstanding firm in the fields of Blockchain, M&A, Investment Funds, International Trade and Capital Markets.

See the full rankings here: https://www.duns100.co.il/en/rating/Law_Firms

Yuval Horn will co-chair the 4th Annual Mergers and Acquisitions in the Technology Sector Conference of the International Bar Association, to take place on March 28-29, 2019 in Barcelona.

February 2019

The annual conference brings together professionals from leading international law firms, to debate the hottest issues in M&A in the technology industry.

For more information:

https://www.ibanet.org/Conferences/conf944.aspx

Horn & Co. was recognized by Chambers and Partners as a leading firm in FinTech stating: “They are best known within FinTech for their work on blockchain and tokenisation, with a number of cutting-edge and highly respected mandates in the area.” Yuval Horn was ranked as a leading individual stating: ‘Clients describe Horn as a “smart, efficient and professional” lawyer who is “doing excellent work on ICOs.”’.

November 2018

For more info:

https://chambers.com/profile/department/351707?publicationTypeId=49&practiceAreaId=2744&locationId=116&subsectionTypeId=1

Proud of our partner, Keren Kanir, who was included in the impressive list of the leading female lawyers in Israel, naming her as a notable Israeli practitioner in corporate-biotech.

November 2018

for more info:

מלומדות – עמוד הבית

Congratulations to our client, IOPtima Ltd., on the completion of the second stage of its acquisition transaction with Chengdu Kanghong Pharma Group Co. Ltd. Horn & Co. team was led by Yuval Horn, Paz Abercohen and Uri Dotan.

September 2018

for more info:

https://www.linkedin.com/feed/update/urn:li:activity:6452420104624832512

Horn & Co. represented Spacemesh in a Series A $15M financing round led by Polychain Ventures, with participation from the world’s leading blockchain oriented investment funds. The Horn & Co. team was led by Yuval Horn, Ohad Mamann and Maya Weiss Donin. Tomer Afek, Aviv Eyal and Ifat Linur – congratulations on this impressive milestone!

For more info: https://spacemesh.io/funding/

Proud to lead the list of top Israeli firms specializing in Hi-tech with an equal number of female and male partners, as described in this interesting article by @themarker.

https://www.themarker.com/technation/.premium-MAGAZINE-1.6360247

Yuval Horn and Keren Kanir of Horn & Co. represented Anima Biotech in an exclusive collaboration agreement with Eli Lilly, with a total deal value exceeding $1 billion.

For more info:

https://www.prnewswire.com/news-releases/anima-biotech-announces-an-exclusive-collaboration-with-lilly-for-the-discovery-and-development-of-translation-inhibitors-of-several-protein-targets-876239046.html

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s small size belies the reputation it enjoys with regard to the commercialisation of intellectual property.

June, 2018

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s small size belies the reputation it enjoys with regard to the commercialisation of intellectual property. Having a team of “very professional, experienced and skilful patent lawyers” it has long been punching above its weight”. Partner Yuval Horn was noted as one of top 3 “highly recommended” individuals, quoting one client: “He’s one of the best – if not the best – transactional lawyers in Israel..” Partner Ohad Mamann was recommended as a leading individual, noting: he “has a singular knowledge of venture-capital issues and relishes the challenge of securing a cross-border agreement.” For more info:

http://www.iam-media.com/patent1000/rankings/Detail.aspx?g=f35c5ba6-3ee4-4cdb-9f7c-c2fafaa422a4#Firms__transactions

Congratulations to our client, Zebra Medical for closing an impressive $30M financing round led by aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation and additional new and current investors.

June, 2018

Congratulations to our client, Zebra Medical for closing an impressive $30M financing round led by aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation and additional new and current investors. Horn & Co.’s team was led by Yuval Horn and Uri Dotan.

For more info:

https://techcrunch.com/2018/06/07/zebra-medical-vision-gets-30m-series-c-to-create-ai-based-tools-for-radiologists/

Yuval Horn chosen as “Thought Leader” of Life Sciences Transactions by Who’s Who Legal: Life Sciences 2018.

May 2018

Yuval Horn chosen as “Thought Leader” of Life Sciences Transactions by Who’s Who Legal: Life Sciences 2018. The publication indicates: “Thought leader Yuval Horn of HORN & CO LAW OFFICES tops our listings in Israel thanks to his “vast experience in the life sciences space”. He is a “very talented” lawyer and is internationally regarded as “a big name” in the market.” http://whoswholegal.com/news/analysis/article/34371/life-sciences-2018-transactional-analysis/

Yuval was also asked to share his insights with respect to the 2018 Life Sciences transactional market:

http://whoswholegal.com/news/features/article/34485/comments-2017-life-science-transactions-outlook-2018/

Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences.

April, 2018

Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “Acting for corporates and sector-specific investors, Horn & Co has a strong reputation in the Israeli life sciences and pharmaceuticals industry. Yuval Horn has considerable experience in cross-border commercial contracts, partnership agreements, financing and M&A”. The firm was also recognized as a leading firm in the field of Hi-Tech and Start Ups, noting that: “Horn & Co is one of the best-known names in Israel’s biotech and pharmaceuticals sector. Led by Yuval Horn, the team advises VC investors and Israeli start-ups on cross-border financing, M&A and licensing agreements”.

For more info:

http://www.legal500.com/c/israel/healthcare-and-life-sciences

Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led  a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.

February 2018

Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led  a €16 million Series A round and restructuring in ABAC Therapeutics, Inc., a leader in pathogen-specific antibiotics. The impressive syndicate of experienced life science investment funds and strategic pharma partners included Pontifax, Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

For more information:

http://www.abactherapeutics.com/news/abac-therapeutics-announces-16-million/

Yuval Horn, Paz Abercohen and Uri Dotan of Horn & Co. represented IOptima Ltd. and its shareholders, including Biolight Life Sciences Investments Ltd (TASE: BOLT) in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million, with Chengdu Kanghong Pharmaceutical Group, a Chinese life sciences company listed on the Shenzhen stock exchange.

November 2017

Read more here

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. (Nasdaq: VBLT) in its $18.75 Million follow-on offering on NASDAQ.

November 2017

Read more here.

Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $9 Million private notes exchange agreement, and a $10 Million private placement of the company’s Secured Convertible Notes.

July 27, 2017

Read more here.

Horn & Co. ranked, again, by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions

June, 2017

Horn & Co. ranked, again, by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions:  “Horn & Co is in its element when commercialising intellectual property; its finely honed business instincts ensure that it can identify the best routes to maximise portfolio value”. Partners Yuval Horn and Ohad Mamann were recommended as leading individuals: “’Yuval and Ohad are among the best corporate attorneys in the country, and have been instrumental securing licence agreements for us,’ enthuses one client”. Read more here: http://www.iam-media.com/patent1000/rankings/Detail.aspx?g=7bebd694-1b48-4d68-bcfa-8668b0003f18

Yuval Horn, Keren Kanir, Ohad Mamann and Tammy Alon of Horn & Co., Law Offices represented Eloxx Pharmaceuticals Ltd. in its Series C financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc.

Read more here.

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “the firm has been active at the ‘top level’ in the healthcare sector for over 20 years”

April 2017

Read more here

Yuval Horn, Roy Ribon and Yasmin Zohar of Horn & Co. acted as Israeli counsel to Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), in its listing on Nasdaq and offering of $12 million

March 2017

Read more here

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise

March 2017

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise. Firm was ranked a leader (“tier 1”) firm in the field of Hi-Tech, and as an outstanding firm in the fields of Intellectual Property, M&A, Investment Funds and Capital Markets.

See the full rankings here: http://wink.globes.co.il/docs/law2017_table_only.pdf

Yuval Horn was noted as one of leading practitioners in Israel in the field of Information Technology by the 2017 edition of Who’s Who Legal: Telecommunications Media & Technology

January 2017

Read more here

Adv. Paz Abercohen joined the firm as a partner

January 2017

Yuval Horn and Ohad Mamann of Horn & Co. represented the investors in ArtsAvit’s financing round, led by Pontifax, Arkin Holdings and Merck Ventures

January 2017

Read more here

Vascular Biogenics Ltd. (NASDAQ:VBLT) Announces $24 Million Registered Direct Offering

December 2016

Read more here

Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 Million private notes exchange agreement, and a $22.5 Million private placement of the company’s Secured Convertible Notes

December 2016

Read more here

IBA 2nd M&A conference in the technology sector crowned with success

October 2016

The conference, held at the Hilton hotel in Tel-Aviv, was coordinated by Clara Ann Gordon, Yuval Horn and Jocelyn Kelley, and brought together 140 delegates from 35 countries (including 55 from Israel). The conference included a keynote speech by Avi Hasson, the Chief Scientist, panels covering hot topics in both M&A and technology, a joint dinner in Jaffa and several social events.

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2016

June 2016

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2016 – bringing together five leading experts to discuss issues facing life sciences lawyers and their clients today.

Read more here

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. in its $24 Million follow-on offering on NASDAQ

June 2016

Read more here

Horn & Co. listed by iam Magazine as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions

May 2016

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions, stating: “Horn & Co is “a great office for licensing”…the group shines at the commercialization of innovative technologies… Hotly tipped for his business acumen, Yuval Horn is a consummate dealmaker”.
Read more here

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare

May 2016

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare, with participation of Dolby Ventures, Ourcrowd, Marc Benioff and Khosla Ventures.

Read more here

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round

May 2016

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare, with participation of Dolby Ventures, Ourcrowd, Marc Benioff and Khosla Ventures.

Read more here

Yuval Horn and Keren Margalit of Horn & Co. represented BioSight Ltd. in its Series B financing round led by Arkin Holdings and US based venture firm Primera Capital

May 2016

Read more here

Yuval Horn to moderate the corporate finance panel at the IBA 4th Annual World Life Sciences Conference on July 3, 2016 in San Francisco

May 2016

For more information: IBA 4th Annual World Life Sciences Conference

Yuval Horn and Ohad Mamann of Horn & Co. represented the lead investors in cancer metabolism start-up Metabomed’s series A financing round

April 2016

Yuval Horn and Ohad Mamann of Horn & Co. represented the lead investors in cancer metabolism start-up Metabomed’s series A financing round, led by Pontifax and Arkin Holdings, and including the venture arms of Merck, Boehringer Ingelheim and Pfizer and the Technion Research and Development Foundation.

For more information: http://www.globes.co.il/en/article-cancer-metabolism-co-metabomed-raises-18m-1001114888

Yuval Horn will co-chair the 2nd Annual Mergers and Acquisitions in the Technology Sector Conference of the International Bar Association, to take place on October 27-28, 2016 in Tel Aviv

April 2016

The annual conference brings together professionals from leading international law firms, to debate the hottest issues in M&A in the technology industry.

For more information: http://www.ibanet.org/Article/Detail.aspx?ArticleUid=f22720f1-f644-4225-9368-07c59730179a

Adv. Orly Sternfeld joined the firm as a partner

January 2016

Yuval Horn to participate in an Executive Briefing about: Risks and Rewards of Expanding into the United States, on January 31, 2016

January 2016

Yuval Horn will participate in an Executive Briefing to be hosted by the Israel-America Chamber of Commerce and Mintz Levin about: Risks and Rewards of Expanding into the United States, on January 31, 2016.

Read more here.

Yuval Horn and Orly Sternfeld of Horn & Co. advised Zebra Medical Vision Ltd. in its collaboration agreement with Dell Services to enable next-generation clinical insights and better population health management

November 2015

Read more: http://www.businesswire.com/news/home/20151124005037/en/Dell-Services-Leverages-Big-Data-Analytics-Cloud

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. in its $15 Million follow-on offering on NASDAQ

November 2015

Read more here: VBL follow-on offering

Yuval Horn was announced as the incoming Co-Chair of the International Bar Association Technology Law Committee

October 2015

Yuval Horn was announced as the incoming Co-Chair of the International Bar Association Technology Law Committee, effective January 1, 2016, for 2 years. The Committee includes 600 professionals from many countries with expertise in technology related transactions of all types. Its subcommittees include specialty focus on outsourcing, life sciences, internet business, corporate information, and disputes and rights. Yuval is the 3rd Israeli to have been elected as a Chairperson of any professional committee of the IBA. http://www.ibanet.org/LPD/IP_Comm_Tech_Section/Technology_Law/Default.aspx

Yuval Horn to moderate a panel relating to Regulation of Genetic Testing at the IBA Annual Conference in Vienna in October, 2015

September 2015

Horn & Co. represented cCam Biotherapeutics Ltd. and its shareholders in the acquisition by Merck Sharp & Dohme for $605 million.

July 2015

Read more about it here:

http://www.businesswire.com/news/home/20150728005731/en/Merck-Enhances-Immuno-Oncology-Portfolio-Acqu#.Vbd1sPmqqko

Taboola.com increases its $117 million private financing round, and closes follow-on investments with Baidu Inc. and DailyMail.com.

June 2015

http://blogs.wsj.com/digits/2015/05/18/baidu-invests-in-content-recommendation-company-taboola

http://blogs.wsj.com/cmo/2015/06/04/dailymail-com-invests-3-million-in-web-content-marketing-firm-taboola/

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.

June 2015

http://www.iam-media.com/Patent1000/Rankings/Detail.aspx?g=ceb9f83d-2e12-4d12-a80d-d9077e16ad23

Biolight Israeli Life Sciences Investments Ltd (TASE: BOLT) executes memorandum for strategic cooperation in China and closes $6.2 million investment with investors based in Hong Kong.

May 2015

Angioslide Ltd. closes a strategic license agreement for the Asian market and round D investment round with a consortium of Chinese investors.

April 2015

Polyheal Ltd. enters into a manufacturing and distribution license agreement with Praxis Pharmaceutical S.A.

April 2015

Intec Pharma Ltd. enters into a Research, Option and Licensing Agreement with one of the world’s top 20 pharmaceutical companies, in terms of market cap.

April 2015

http://intecpharma.com/press-release/signing-of-an-agreement-with-a-global-pharmaceutical-company

Yuval Horn noted as one of 5 most highly regarded practitioners worldwide in life sciences transactions

March 2015

http://whoswholegal.com/news/analysis/article/32123/legal-marketplace-analysis/?utm_source=Law+Business+Research&utm_medium=email&utm_campaign=5460489_WHO+Briefing&dm_i=1KSF,391C9,9GRLTC,BMYM0,1

Cellera, Inc. closes asset purchase agreement for undisclosed amount

March 2015

Yuval Horn will co chair the keynote and corporate finance panels at the upcoming IBA World Life Sciences Conference on June 12 in Philadephia

March 2015

Philadelphia Conference- IBA- June 2015

Yuval Horn to co chair the keynote 5/10 Trend panel: “what are the emerging life sciences business models and what will they look like in five years and ten years from now?” at the IBA 3rd World Life sciences Conference.

In addition, Yuval will co chair the Panel: “Financing life sciences companies – what’s current and what’s new”.

Taboola.com closes $117 million private financing round

February 2015

Read more about it here: http://blogs.wsj.com/digits/2015/02/04/content-marketing-company-taboola-raises-117-million/?KEYWORDS=taboola

Adv. Roy Ribon and Adv. Ohad Mamann joined the firm as partners

January 2015

Yuval Horn nominated Vice Chairman of the International Bar Association Technology Law Committee.

December 2014

Medivation Inc. (represented by Horn & Co.) Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd.

October 2014

Read more here: http://investors.medivation.com/releasedetail.cfm?ReleaseID=877968

Yuval Horn will moderate a panel at the upcoming IBA Annual Conference in Tokyo, Japan (October 2014).

October 2014

Yuval Horn will moderate a panel, titled “Telemedicine by satellite: improving health care and creating legal and ethical issues”, at the IBA’S UPCOMING ANNUAL CONFERENCE IN TOKYO, JAPAN.

Yuval Horn will join a panel at the upcoming IBA Annual Conference in Tokyo, Japan (October 2014).

October 2014

Yuval Horn will join a panel on “License to Kill” in the upcoming International Bar Association Annual conference in Tokyo on October 22, 2014.

Amnon Ovadia (Babylon Software Ltd.) purchases the translation business from Babylon Ltd. (TASE)

September, 2014

Amnon Ovadia (Babylon Software Ltd.) purchases the translation business from Babylon Ltd. (TASE)

V-Gen Ltd.’s shareholders sell all of their shares to Newport Corporation.

July 2014

V-Gen Ltd.’s shareholders sign an agreement for the sale of all of their shares to Newport Corporation.

Vascular Biogenics Ltd. announced the pricing of its initial public offering.

July 2014

Vascular Biogenics Ltd. announced the pricing of its initial public offering. The shares are scheduled to begin trading on the NASDAQ Global Market on July 31, 2014 under the ticker symbol “VBLX.” The offering is expected to close on August 5, 2014, subject to customary closing conditions.

Horn & Co. listed by iam Magazine as one of the top 6 recommended Israeli firms in the field of IP transactions.

June 2014

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of IP transactions

Content discovery business Taboola strikes deal with Yahoo Japan

June 2014

Content discovery business Taboola strikes deal with Yahoo Japan

WE MOVED. Our new offices are located at…

April 2014

WE MOVED.
Our new offices are located at:
Amot Investments Tower
2 Weizmann St., 24th Floor
Tel Aviv 6423902, Israel

Yuval Horn participates in the Who’s Who Legal’s Roundtable: Life Sciences 2014.

March 2014

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2014: TRANSACTIONAL – Who’s Who Legal brings together two of the leading practitioners in the world to discuss key issues facing transactional specialists today.

Yuval Horn will chair the Keynote Panel at the 2nd Annual IBA World Life Sciences Meeting.

February 2014

Yuval Horn will chair the Keynote Panel at the 2ND ANNUAL IBA WORLD LIFE SCIENCES MEETING, IN JUNE 2014, SAN DIEGO, CA USA. The Keynote Panel is titled “5/10 Trend Panel – what are the emerging life sciences business models and what will they look like in 5 years and 10 years from now?”

CollPlant Holdings Ltd. completes a public offering.

December 2013

Read more here: http://www.themarker.com/markets/1.2198545

Horn & Co. assisted the public companies association in outlining a proposed modification to the guidelines for disclosure of biomed companies.

December 2013

Disclosure requirements and analysis model for biomed companies – Horn & Co. assisted the public companies association in outlining a proposed modification to the guidelines for disclosure of biomed companies, at a conference held at the Tel-Aviv Stock Exchange on December 23, 2013.

Yuval Horn to co-chair a panel at the upcoming IBA Annual Conference in Boston (October 2013).

September 2013

Yuval Horn to co-chair a panel on “Building a Winning Team in Technology Companies” at the upcoming International Bar Association Annual Conference on October 9, 2013 in Boston

Immune Pharmaceuticals Ltd. completes its merger with the US publicly traded company Immune Pharmaceuticals Inc.

August 2013

Immune Pharmaceuticals Ltd., a privately held Israeli company, completes its merger with the US publicly traded company Immune Pharmaceuticals Inc. (formerly known as EpiCept Corporation) (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD).

VIM Technologies Ltd. is acquired by Presstek (Israel) Ltd.

August 2013

VIM Technologies Ltd. is acquired by Presstek (Israel) Ltd.

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.

August 2013

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.

Horn & Co. Represents the Israeli Public Companies Organization in its dialogue with the ISA.

May 2013

Read more here: http://www.globes.co.il/news/article.aspx?did=1000839127

Yuval Horn to co-chair a panel at the IBA World Life Sciences Conference in Dallas, Texas.

May 2013

Yuval Horn to co-chair a panel on Tech Transfer Tactics at the IBA World Life Sciences Conference in Dallas, Texas, USA ( IBA LIFE SCIENCES CONFERENCE)

Yuval Horn noted as one of the 5 worldwide leading practitioners in Life Sciences Transactions.

April 2013

The 2013 editorial of the Who’s Who Life Sciences notes Yuval Horn as one of the 5 worldwide leading practitioners in Life Sciences Transactions and states: “Yuval Horn of Horn & Co. Law Offices in Israel was repeatedly cited as ‘the best in the market’. He is well versed in all transactional aspects of the sector, including licensing and sale of technology, joint ventures and other commercial transactions”

Chambers Global ranks Yuval Horn as a leading Israeli practitioner in M&A: High Tech

March 2013

Chambers Global ranks Yuval Horn as a leading Israeli practitioner in M&A: High Tech

Yuval Horn nominated as Chairperson of the IBA LifeSciences SubCommittee.

December 2012

Yuval Horn nominated as Chairperson of the IBA LifeSciences SubCommittee.

Immune Pharmaceuticals Ltd., and EpiCept Corporation entere into a definitive merger agreement.

November 8, 2012

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation (NASDAQ OMX Stockholm Exchange and OTCQX: EPCT) today announced that they have entered into a definitive merger agreement.

Yuval Horn chairs a panel at the IBA Annual Conference in Dublin, Ireland (October 2012).

October, 2012

Double Irish Licensing Agreements – Yuval Horn chairs a panel with respect to Double Irish structures at the IBA Annual Conference in Dublin, Ireland (IBA ANNUALCONFERENCE).

ILS Brokers Ltd.’s shareholders sell all of their shares to Leader Capital Markets Ltd.

May, 2012

ILS Brokers Ltd. signs an agreement for the sale of all of its shares to Leader Capital Markets Ltd., in consideration for 10% of Leader’s shares and NIS 10 million.

Pfizer, Inc. and Protalix BioTherapeutics, Inc. announce that the FDA approved ELELYSO™.

May, 2012

New York, NY/Carmiel, Israel, May 1, 2012 – Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease.

Protalix BioTherapeutics, Inc. raised over $25 million on AMEX.

February, 2012

Protalix BioTherapeutics, Inc. raised over $25 million following the sale of approximately 5 million shares on AMEX.

A merger of Gardia Medical Ltd. with Allium Medical Solutions Ltd.

January, 2012

A merger of Gardia Medical Ltd. (“Gardia”), a private company controlled by the venture capital funds group Medica Venture Partners, with Allium Medical Solutions Ltd. (“Allium”), in which all of the issued capital of Gardia was acquired. As part of the agreement, Allium shall invest at least US$ 3.5 million in the development of Gardia’s products, which regard to various solutions to emboli formed during catheterization.

Yuval Horn elected as an expert in Life Sciences by Who’s Who of Life Sciences Lawyers 2012.

November, 2011

Yuval Horn elected as an expert in Life Sciences by Who’s Who of Life Sciences Lawyers 2012.

Vision BI shareholders sell controlling interest to Keyrus, SA.

October, 2011

Vision BI shareholders sell controlling interest to Keyrus, SA.

Completion of a merger of IBI Biomedical Innovations Ltd. with Allium Medical Solutions Ltd.

September 8, 2011

Completion of a merger of IBI Biomedical Innovations Ltd. (“IBI”) with Allium Medical Solutions Ltd. (“Allium”) in which all of the issued capital of IBI was acquired in consideration for 49.93% of the issued and paid up capital of Allium and its voting rights. In addition, Allium had allocated to IBI employees, consultants and officers non-negotiable option warrants.

Gefen Biomed Investments Ltd. files Shelf Prospectus with ISA.

August 22, 2011

Gefen Biomed Investments Ltd. files Shelf Prospectus with Israel Securities Authority.

Yuval Horn speaks at a dinner party for the French Delegation to THE ILSI-BIOMED 2011 CONFERENCE

May, 2011

Yuval Horn speaks at a dinner party for the French Delegation to THE ILSI-BIOMED 2011 CONFERENCE hosted by the Chamber of Commerce Israel – France.